Dr Phil Boyd has held senior finance roles in various private and public life science companies for 20+ years. He was CFO of Syntaxin Ltd from 2007 through to the acquisition by Ipsen in July 2013, CFO of Tiziana Lifesciences plc (AIM: TILS) from its IPO in 2014 to 2015, and CFO of Oxford BioDynamics plc (AIM: OBD) ahead of its AIM listing in 2016. Prior to Syntaxin he was UK Finance Director of Evotec AG (2001-2007) and Finance Director of Cambridge Discovery Chemistry from 1999 until its acquisition by Millennium Pharmaceuticals in 2001. He currently serves as CFO with Enterprise Therapeutics, and as a Non-Executive Director with UK BioCentre Ltd. He has a BSc in Biotechnology and a PhD in Genetics from University of Leeds, and is a qualified management accountant (ACMA).